All In Biotech

Drug Trial Radar · NCT07777133

A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants

A Phase 1 Study to Evaluate the Mass Balance, Metabolism, Excretion, and Pharmacokinetics of [14C]Navlimetostat (BMS-986504) at Steady State in Healthy Female Participants

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Sep 29, 2026

Primary completion

Dec 5, 2026

Study completion Dec 5, 2026

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the metabolism, the routes and extent of elimination, and drug levels of \[14C\]Navlimetostat (BMS-986504) in healthy female participants

Conditions

  • Healthy Female Participants

Interventions

  • NavlimetostatDrug

    Specified dose on specified days

  • [14C]NavlimetostatDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum observed plasma concentration (Cmax)Time frame: Up to 14 days
  2. Time of maximum observed plasma concentration (Tmax)Time frame: Up to 14 days
  3. Area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC(0-T))Time frame: Up to 14 days
  4. Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF))Time frame: Up to 14 days
  5. Terminal elimination half-life (T-HALF)Time frame: Up to 14 days
  6. Apparent total body clearance (CLT/F)Time frame: Up to 14 days
  7. Apparent volume of distribution during the terminal phase (VZ/F)Time frame: Up to 14 days
  8. Percent of plasma navlimetostat AUC(INF) to plasma radioactivity AUC(INF) (%AUC(INF))Time frame: Up to 14 days
  9. Total radioactivity (TRA) ratio of blood AUC(INF) to plasma AUC(INF)Time frame: Up to 14 days
  10. Total amount of dose recovered in urine (UR)Time frame: Up to 14 days
  11. Percent of administered dose recovered in urine (%UR)Time frame: Up to 14 days
  12. Renal clearance (CLR)Time frame: Up to 14 days
  13. TRA from URTime frame: Up to 14 days
  14. TRA from %URTime frame: Up to 14 days
  15. TRA from total amount of dose recovered in feces (FR)Time frame: Up to 14 days
  16. TRA from percent of administered dose recovered in feces (%FR)Time frame: Up to 14 days
  17. TRA from total amount of radioactivity recovered (Rtotal)Time frame: Up to 14 days
  18. TRA from total percent of radioactivity recovered (%TOTAL)Time frame: Up to 14 days
  19. TRA amount recovered of the radioactive dose in vomit, if applicableTime frame: Up to 14 days
  20. TRA fraction of the radioactive dose in vomit, if applicableTime frame: Up to 14 days

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Local Institution - 0002

    Madison, Wisconsin · Not yet recruiting

  • ICON Netherlands - Groningen

    Groningen, Provincie Groningen, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.